ArticleJournal of translational medicine2026
CA9 targets ITGB1 to accelerate the progression of colorectal cancer by promoting the neutrophil extracellular traps formation.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundThe immunological role of carbonic anhydrase IX (CA9) in colorectal cancer (CRC) progression remains undefined. This study reveals a CA9-driven mechanism promoting tumor progression through neutrophil extracellular traps (NETs).
methodsCA9 was identified as a candidate oncogene in CRC through public single-cell RNA sequencing data screening. Endogenous modulation of CA9 in vitro and in vivo was performed to elucidate its function. Flow cytometry and immunofluorescence assays were employed to assess how CA9 promotes neutrophil infiltration and NETs formation in tumor tissues. Finally, molecular docking, co-immunoprecipitation, and cytokine arrays were integrated to investigate the specific mechanisms of CA9-driven CRC progression.
resultsSerum CA9 expression level in CRC patients exhibited significantly elevated relative to controls, correlating with poor clinical prognosis (P < 0.05). Interestingly, CA9 mainly played a significant pro-tumor role in CRC mouse models, promoting tumor progression by regulating neutrophil recruitment and NETs formation. Mechanistically, CA9 binds to ITGB1, activating the NF-κB pathway and triggering increased secretion of C-X-C motif chemokine ligand 8 (CXCL8), which subsequently promoted neutrophil recruitment and NETs formation. Thus, the CA9-ITGB1-CXCL8 axis induces neutrophil reactive oxygen species production and NETs formation, thereby promoting CRC tumor progression.
conclusionThe CA9-driven ITGB1-CXCL8-NETs signaling axis significantly promotes CRC progression, thereby establishing CA9 as a novel potential therapeutic target for CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.